Global Partners LP (GLP)

Eli Lilly said on Wednesday its oral drug, orforglipron, helped reduce blood sugar levels in two late-stage trials.

WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (the “Partnership”) today announced that the Board of Directors (the “Board”) of its general partner, Global GP LLC, has declared a quar...

Global Partners LP is a leading midstream and retail energy MLP with strong cash flows and a robust, vertically integrated business model. GLP's recent acquisitions and disciplined capital management ...

Novo Nordisk is well-positioned in the obesity drug market, with strong financials and anticipation for its oral Wegovy pill. NVO's first-half 2025 results showed robust growth, driven by obesity fran...

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF) CEO Jeremy Skillington talked with Proactive about the company's interim results and key clinical milestones. Skillington highlighted that Poolbeg ended June w...

Global Partners preferred stock's 9.2% dividend remains safe, backed by strong business momentum and resilient cash flow. GLP operates 1,700 fueling stations, benefiting from economies of scale and a ...

Fractyl Health delivered best-case results from its REMAIN-1 trial, with Revita patients continuing weight loss after GLP-1 discontinuation while placebo significantly rebounded. GUTS is still ~$230 m...

Over the past five years, Eli Lilly (LLY 1.43%) has outperformed the broader market, largely thanks to its progress in the GLP-1 arena. Its major breakthroughs in the field are already leading to incr...

AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #AI--MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company, today announced a major advancement of its AI-desi...

NVO gains ground in the GLP-1 battle as Ozempic outshines Trulicity in heart risk reduction and Rybelsus wins EU approval for added benefits.